Physician profile
Gregory Lynch
NPI 1790008175
$11,364.89
in general payments reported to CMS, 2019-2025
23 companies · $3,160 in 2025
The $3,160 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,792 · 2022: $1,696 · 2023: $2,177 · 2024: $1,539 · 2025: $3,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,668 · Consulting Fee: $1,080 · Education: $128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,668.29 |
| Consulting Fee | $1,080.00 |
| Education | $127.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,275.38 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $2,063.20 | 2021-2025 | Winlevi, Absorica Ld, Ilumya |
| Genzyme Corporation | $1,646.58 | 2021-2025 | |
| Janssen Biotech, INC. | $1,083.69 | 2021-2025 | Tremfya |
| Ucb, INC. | $643.52 | 2021-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $613.33 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $469.80 | 2021-2025 | Dupixent, Libtayo |
| Pfizer INC. | $380.05 | 2021-2025 | |
| Amgen INC. | $377.64 | 2022-2025 | Otezla, Otezla |
| Leo Pharma INC. | $376.99 | 2022-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $264.60 | 2023-2024 | Sotyktu, Opdivo |
| Lilly USA, LLC | $250.71 | 2021-2025 | Ebglyss |
| Incyte Corporation | $196.42 | 2021-2025 | Opzelura |
| Journey Medical Corporation | $170.66 | 2021 | |
| Sanofi-Aventis U.S. LLC | $147.43 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $115.30 | 2023-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.03 | 2022-2025 | Spevigo |
| Genentech USA, INC. | $52.16 | 2021-2023 | Erivedge |
| Organon LLC | $34.66 | 2025 | Vtama |
| Fresenius Kabi USA, LLC | $34.64 | 2024 | |
| Galderma Laboratories, L.P. | $29.28 | 2025 | Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.51 | 2021 | |
| Allergan, INC. | $19.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Lynch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.